Page 23 - pesta2014_3

SOVALDI® transforms HCV

therapy, allowing many more

patients the opportunity of cure

• The first nucleotide polymerase inhibitor with
pan-genotypic activity and a high barrier to
resistance
1
• ≥90% cure across all genotypes with only 12
weeks of SOVALDI + Peg-IFN + RBV in previously
1
untreated adults *
• An all-oral 24-week option available for those
patients unsuitable for Peg-IFN 1
• No adverse drug reactions specific to SOVALDI 1
– In the context that SOVALDI has mainly been
studied in combination with RBV, with or without
Peg-IFN

* 12-week all-oral SOVALDI + RBV
regimen for GT 2.

Jan 2014 HCV/ND/14-03/PM/1160

Gilead Sciences Nordic Office | Hemvärnsgatan 9, SE-171 54 Solna, Sweden | Phone: + 46 (0)8 505 71 800 | Fax: + 46 (0)8 505 71 801